2315504-40-4

2315504-40-4 structure
2315504-40-4 structure
  • Name: DA-JC4
  • Chemical Name: DA-JC4
  • CAS Number: 2315504-40-4
  • Molecular Formula: C225H346N56O65
  • Molecular Weight: 4875.49
  • Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK Insulin Receptor
  • Create Date: 2021-09-04 23:08:16
  • Modify Date: 2025-08-25 11:08:58
  • DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways[1][2][3].

Name DA-JC4
Description DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways[1][2][3].
Related Catalog
Target

GLP-1/GIP[1]

In Vitro DA-JC4 (1~100 nM; hippocampal cells) inhibits rotenone-induced hippocampal neuron death and significantly suppresses Cyt C, Bax and Caspase activation[3].
In Vivo DA-JC4 (10 nmol/kg; i.p.; once-daily for 14 days) significantly prevents spatial learning deficits in a Y- maze test and Morris water maze tests, and decreases phosphorylated tau levels in the rat cerebral cortex and hippocampus[1]. DA-JC4 (25 nmol/kg; i.p.; 6 days) shows high levels expression of tyrosine Hydroxylase in the s. nigra and increases expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF)[2]. DA-JC4 (50 nmol/kg; i.p.; once-daily for 7 days) improves Parkinson's disease symptom potentially and enhances neurotransmission[3]. Animal Model: Male Sprague-Dawley rats (210–230 g) Dosage: 10 nmol/kg Administration: I.p. Result: Significantly prevented spatial learning deficits in a Y- maze test and Morris water maze tests, and decreased phosphorylated tau levels in the rat cerebral cortex and hippocampus. Animal Model: Adult male C57BL/6 mice (8 week-old) Dosage: 25 nmol/kg/day Administration: I.p. Result: Showed high levels expression of tyrosine Hydroxylase in the s. nigra and increased expression of neuroprotective growth factor Glial-Derived Neurotrophic Factor (GDNF). Animal Model: Adult male Sprague-Dawley (SD) rats (230-280 g) Dosage: 50 nmol/kg Administration: I.p. Result: Improved Parkinson's disease symptom potentially and enhanced neurotransmission.
References

[1]. Shi L, et al. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res. 2017;327:65-74.

[2]. Feng P, et al. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease. Neuropharmacology. 2018;133:385-394.

[3]. Li T, et al. Neuroprotection of GLP-1/GIP receptor agonist via inhibition of mitochondrial stress by AKT/JNK pathway in a Parkinson's disease model. Life Sci. 2020;256:117824.

Molecular Formula C225H346N56O65
Molecular Weight 4875.49
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.